Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.51 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.51 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457976 | 0.94 | HIF1A (0.51) | HIF1AVDAC2SLC7A11CACNA2D1ALDH1A1 | |
| SCHEMBL1593382 | 0.88 | VDAC2 (0.51) | HIF1AVDAC2SLC7A11ALDH1A1KMT2A | |
| SCHEMBL12610306 | 0.87 | VDAC2 (0.61) | HIF1AVDAC2SLC7A11CACNA2D1KMT2A | |
| SCHEMBL4456692 | 0.87 | HIF1A (0.67) | HIF1AVDAC2SLC7A11CACNA2D1ALDH1A1 | |
| SCHEMBL12703613 | 0.84 | ALDH1A1 (0.50) | HIF1AVDAC2SLC7A11ALDH1A1KMT2A | |
| SCHEMBL4459138 | 0.82 | SLC7A11 (0.80) | VDAC2SLC7A11ALDH1A1KMT2AMAPK1 | |
| SCHEMBL13633741 | 0.80 | VDAC2 (0.63) | HIF1AVDAC2SLC7A11ALDH1A1SMN1; SMN2 | |
| SCHEMBL13789539 | 0.80 | HIF1A (0.55) | HIF1AVDAC2SLC7A11CACNA2D1GAA | |
| SCHEMBL13633615 | 0.80 | VDAC2 (0.63) | HIF1AVDAC2SLC7A11ALDH1A1KMT2A | |
| SCHEMBL13633665 | 0.79 | VDAC2 (0.59) | HIF1AVDAC2SLC7A11ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | BAD, CASP3, BAX | HIF1A 910/4885VDAC2 801/4885SLC7A11 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.